Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC)

M. G. Fury, E. J. Sherman, Shyam Rao, S. Wolden, S. Smith-Marrone, B. Mueller, K. K. Ng, P. R. Dutta, D. Y. Gelblum, J. L. Lee, R. Shen, S. Kurz, N. Katabi, S. Haque, N. Y. Lee, D. G. Pfister

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC)'. Together they form a unique fingerprint.

Medicine & Life Sciences